April 27, 2020: Novacyt, an international specialist in clinical diagnostics, announces it has signed a supply contract with the UK Department of Health and Social Care (DHSC) for its COVID-19 (CE IVD) polymerase chain reaction (PCR) test, developed by Primerdesign, the Company’s molecular diagnostics division based in the UK.
Under the terms of the agreement, Novacyt will supply its COVID-19 test to the DHSC for an initial term of six months, starting from 4 May 2020. Novacyt has initially committed to supply 288,000 tests per week to the DHSC for use in the NHS, with the option to expand the agreement.
This partnership with the DHSC reinforces Novacyt’s existing support of the UK government’s five-pillar plan to increase testing for COVID-19.
The contract is in addition to the Company’s collaboration with AstraZeneca, GSK and the University of Cambridge, announced on 8 April 2020, where Novacyt is committed to ensure an effective workflow process within the facility for COVID-19 testing, as well as provide its COVID-19 test to generate results data.
Graham Mullis, Chief Executive Officer of Novacyt, commented: “Novacyt is committed to fighting the global COVID-19 pandemic. This partnership with the UK’s Department of Health and Social Care reinforces Novacyt’s position as a leading supplier of COVID-19 tests to the NHS.”
https://novacyt.com/wp-content/uploads/2020/04/Novacyt-DHSC-contract-ENGLISH-27.04.2020.pdf
